CA
ELDN icon

Clearstead Advisors’s Eledon Pharmaceuticals ELDN Stock Holding History

Clearstead Advisors’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.54K Hold
500
– – ﹤0.01% 1953
2025
Q4 		$755 Buy
+500
New +$1.19K ﹤0.01% 2262

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Clearstead Advisors's ELDN Position: Q1 2026 in Review

Clearstead Advisors held its Eledon Pharmaceuticals (ELDN) position steady in Q1 2026 at 500 shares worth $1.54K. The position accounts for ﹤0.01% of the portfolio, ranked #1953.

Clearstead Advisors first reported a position in ELDN in Q4 2025 and has held it in 2 quarters since. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

  • Clearstead Advisors held 500 shares of Eledon Pharmaceuticals worth $1.54K as of Q1 2026.
  • Clearstead Advisors left its Eledon Pharmaceuticals share count unchanged in Q1 2026.
  • Eledon Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q1 2026, its #1953 holding.
  • Clearstead Advisors first reported a position in Eledon Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on Clearstead Advisors's 13F filing for Q1 2026, filed 6 May 2026.